These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32110296)

  • 1. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies.
    Hong H; Zhou Z; Zhou K; Liu S; Guo Z; Wu Z
    Chem Sci; 2019 Oct; 10(40):9331-9338. PubMed ID: 32110296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.
    Hong H; Lin H; Li D; Gong L; Zhou K; Li Y; Yu H; Zhao K; Shi J; Zhou Z; Huang Z; Wu Z
    Angew Chem Int Ed Engl; 2022 Sep; 61(38):e202208773. PubMed ID: 35891606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life.
    Liu J; Hong H; Shi J; Xie Y; Lu Z; Liu Z; Zhou Z; Bian Z; Huang Z; Wu Z
    Eur J Pharm Sci; 2021 Oct; 165():105941. PubMed ID: 34256102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy.
    Hong H; Li C; Gong L; Wang J; Li D; Shi J; Zhou Z; Huang Z; Wu Z
    Chem Sci; 2021 Feb; 12(12):4623-4630. PubMed ID: 34163726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.
    Gong L; Li Y; Cui K; Chen Y; Hong H; Li J; Li D; Yin Y; Wu Z; Huang Z
    Small; 2021 Nov; 17(45):e2103463. PubMed ID: 34761524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
    Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
    J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity.
    Dai S; Hong H; Zhou K; Zhao K; Xie Y; Li C; Shi J; Zhou Z; Nie L; Wu Z
    J Med Chem; 2021 Apr; 64(8):4947-4959. PubMed ID: 33825469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody-dependent cellular phagocytosis of tropomyosin receptor kinase C (TrkC) expressing cancer cells for targeted immunotherapy.
    Lai PS; Usama SM; Kiew LV; Lee HB; Chung LY; Burgess K; Kue CS
    Cancer Immunol Immunother; 2022 Sep; 71(9):2099-2108. PubMed ID: 35032175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 14. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
    Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
    Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
    Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
    Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
    Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
    Front Immunol; 2021; 12():715719. PubMed ID: 34413859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.
    Karpovsky B; Titus JA; Stephany DA; Segal DM
    J Exp Med; 1984 Dec; 160(6):1686-701. PubMed ID: 6239899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
    D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
    Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.